Bluestar Genomics, Inc. Overview
Pro stress-test →Bluestar Genomics delivers epigenomic and big data approaches to reinvent non-invasive molecular diagnostic testing. The company develops liquid biopsy tests based on its proprietary epigenomics platform to detect cancers with high mortality rates early when they respond best to treatment. The company has since rebranded to ClearNote Health while continuing its mission in early cancer detection.
Strategic Profile
Pro stress-test →Founded out of Dr. Stephen Quake's Stanford laboratory, Bluestar Genomics combines novel epigenomic technologies with its novel machine-learning architecture to tackle urgent challenges in cancer detection. The company received FDA Breakthrough Device Designation for a one-of-its-kind assay for patients newly diagnosed with diabetes and at risk for pancreatic cancer. The company's competitive advantage lies in its proprietary 5hmC biomarker platform and early validation from prestigious institutions.
Competitive Landscape
Pro stress-test →Bluestar Genomics competes in the liquid biopsy and early cancer detection market against companies like GRAIL (Illumina subsidiary), Guardant Health, and Foundation Medicine. The company differentiates through its proprietary 5hmC epigenomic biomarker platform and Stanford scientific pedigree. However, it faces competition from well-capitalized competitors with broader test portfolios and established clinical networks.
Industry Context
Bluestar Genomics, Inc. operates in Molecular Diagnostics / Liquid Biopsy / Cancer Detection.
Key facts
Founded: 2016 · Headquarters: San Diego, US